Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome

Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / immunology
  • Cytokine Release Syndrome / drug therapy
  • Cytokine Release Syndrome / immunology
  • Cytokine Release Syndrome / virology*
  • Cytokines / blood
  • Drug Evaluation / methods
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / immunology
  • Receptors, Chimeric Antigen / therapeutic use
  • Receptors, Interleukin-6 / antagonists & inhibitors
  • SARS-CoV-2

Substances

  • Antibodies, Monoclonal, Humanized
  • Cytokines
  • Immunosuppressive Agents
  • Receptors, Chimeric Antigen
  • Receptors, Interleukin-6
  • tocilizumab